Company Overview
About Element Biosciences
Element Biosciences is a genomics company developing next-generation DNA sequencing instruments and reagents designed to democratize access to high-quality, cost-effective sequencing. Founded in 2017 by veterans from Illumina, Life Technologies, and other genomics leaders, the company is headquartered in San Diego, California. Its flagship product, the AVITI System, is a benchtop sequencer that combines high accuracy, flexible throughput, and competitive per-sample costs — making research-grade sequencing accessible to academic labs, biotech companies, agricultural research programs, and clinical settings that previously could not justify large capital outlays for sequencing infrastructure.
Business Model & Competitive Advantage
Element Biosciences raised over $277M in a Series D round in July 2024 led by Wellington Management with participation from Samsung Electronics, Fidelity, Foresite Capital, T. Rowe Price, and Venrock, bringing cumulative funding to over $680M. The AVITI install base grew from approximately 40 units to more than 190 in the 12 months preceding the Series D close — representing substantial commercial momentum in a market dominated by Illumina. The follow-on AVITI24 platform, which combines state-of-the-art sequencing with cyto-profiling in a single integrated instrument, represents the company's expansion into multi-omics and spatial biology workflows.
Competitive Landscape 2025–2026
Element competes directly with Illumina, the long-dominant player in short-read sequencing, as well as with Oxford Nanopore (long-read) and Pacific Biosciences (HiFi). Element differentiates through its proprietary AVITI chemistry — which the company claims delivers fewer errors and lower costs than comparable Illumina platforms — alongside open reagent compatibility that reduces vendor lock-in. The company supports customers across academia, biotech, oncology, agricultural science, and pandemic preparedness in more than 25 countries, with cloud-based data analysis tools completing the end-to-end workflow.
Key Differentiators
Strong Challenger
Element Biosciences is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare Element Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Element Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Element Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Element Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →